HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acquired polycystic kidney disease — Clinical Guidelines

Overview

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder characterized by the proliferation of renal cysts leading to progressive kidney dysfunction and potential renal failure 1 3.

Diagnosis

Clinical Features: Family history, enlarged kidneys, abdominal or flank pain 6.

Imaging: Ultrasound, CT, MRI to identify multiple renal cysts 6.

Genetic Testing: Mutation analysis for PKD1 or PKD2 genes to confirm diagnosis 5.

Laboratory Tests: Elevated creatinine, decreased estimated glomerular filtration rate (eGFR) 1.

Management

First-Line Treatment: Tolvaptan for patients at high risk of rapid progression, though criteria for eligibility vary 2.

Symptomatic Management: Pain relief for symptomatic cysts, management of complications like urinary tract obstruction 18.

Cyst Ablation: Absolute ethanol instillation for symptomatic cysts refractory to medical treatment 10.

Monitoring: Regular assessment of renal function, cyst growth, and complications 1 3.

Special Populations

Pediatrics: Tolvaptan use considered in high-risk pediatric patients, though evidence is evolving 8.

Comorbidities: Increased risk of gout associated with ADPKD; monitor uric acid levels 14.

Key Recommendations

Use Tolvaptan in High-Risk Patients: Consider tolvaptan for slowing renal function decline in patients identified as high risk for rapid progression, though criteria for high risk may vary 2 (Evidence: Moderate).

Regular Monitoring of Renal Function: Implement routine monitoring of eGFR and renal imaging to track disease progression 1 3 (Evidence: Strong).

Genetic Testing for Confirmation: Utilize genetic testing for PKD1 or PKD2 mutations to confirm diagnosis and guide management 5 (Evidence: Moderate).

Manage Symptomatic Cysts: Employ interventions like absolute ethanol ablation for symptomatic cysts unresponsive to medical therapy 10 (Evidence: Weak).

Screen for Comorbid Conditions: Regularly screen for comorbidities such as gout and urinary tract obstruction 14 18 (Evidence: Moderate).

References

1 Smith KA, Thompson AM, Baron DA, Broadbent ST, Lundstrom GH, Perrone RD. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). American journal of kidney diseases : the official journal of the National Kidney Foundation 2019. link 2 Wulfmeyer VC, Auber B, Haller H, Schmitt R. Comparison of Different Selection Strategies for Tolvaptan Eligibility among Autosomal Dominant Polycystic Kidney Disease Patients. American journal of nephrology 2019. link 3 Cho Y, Sautenet B, Rangan G, Craig JC, Ong ACM, Chapman A et al.. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials 2017. link 4 Lantinga MA, Darding AJ, de Sévaux RG, Alam A, Bleeker-Rovers CP, Bobot M et al.. International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection. Nephron 2016. link 5 Robinson C, Hiemstra TF, Spencer D, Waller S, Daboo L, Karet Frankl FE et al.. Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic. BMC nephrology 2012. link 6 Laleye A, Awede B, Agboton B, Azonbakin S, Biaou O, Sagbo G et al.. Autosomal dominant polycystic kidney disease in University Clinic of Nephrology and Haemodialysis of Cotonou: clinical and genetical findings. Genetic counseling (Geneva, Switzerland) 2012. link 7 Russell S. Responding to threats to the kidney. Nursing 2008. link 8 Rizk D, Chapman A. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatric nephrology (Berlin, Germany) 2008. link 9 Cox SM, Starzomski RC. Genes and geneticization? The social construction of autosomal dominant polycystic kidney disease. New genetics and society 2004. link 10 Lee YR, Lee KB. Ablation of symptomatic cysts using absolute ethanol in 11 patients with autosomal-dominant polycystic kidney disease. Korean journal of radiology 2003. link 11 Hallermann C, Mücher G, Kohlschmidt N, Wellek B, Schumacher R, Bahlmann F et al.. Syndrome of autosomal recessive polycystic kidneys with skeletal and facial anomalies is not linked to the ARPKD gene locus on chromosome 6p. American journal of medical genetics 2000. link1096-8628(20000117)90:2<115::aid-ajmg5>3.0.co;2-s) 12 Kumar VS, Babu SK, Agarwal R, Kumar BS, Lakshmi AY, Reddy CK. Hepatic cysts in adult polycystic kidney disease. Indian journal of medical sciences 1997. link 13 Kurtoglu S, Dundar M, Hallaç IK, Uzüm K, Okumuş Y, Oktem T. Polycystic kidney disease, biliary dysgenesis in a patient with Larsen's syndrome. Clinical genetics 1997. link 14 Hosoya T, Ichida K, Tabe A, Sakai O. A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. Nihon Jinzo Gakkai shi 1993. link 15 Panisello JM, Martinez-Vea A, Garcia C, Carrera M, Oliver JA, Richart C. IgA nephropathy and polycystic kidney disease. American journal of nephrology 1988. link 16 Dobranowski J, Somers S, Pirani M. Adult polycystic horseshoe kidney. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes 1986. link 17 Ebeling P, Burke JR, Radford DJ. Endocardial fibroelastosis and infantile polycystic disease. Australian paediatric journal 1985. link 18 Barbaric ZL, Spataro RF, Segal AJ. Urinary tract obstruction in polycystic renal disease. Radiology 1977. link 19 Roy JB, Stevens RK. Polycystic horseshoe kidney. Urology 1975. link90717-7) 20 Carter CO. Polycystic disease presenting in childhood. Birth defects original article series 1974. link

Acquired polycystic kidney disease